A more clinically oriented inquiry may explain why the peritoneal dialysis patients with diabetes showed a stronger response to the increase in erythropoietin dosage and Hct levels in terms of reducing cardiovascular risk. The gene discussed is EPO; the disease is diabetes mellitus.